Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Short term Debt (2022 - 2023)

Orchestra BioMed Holdings (OBIO) has disclosed Short term Debt for 2 consecutive years, with $9.6 million as the latest value for Q3 2023.

  • On a quarterly basis, Short term Debt changed N/A to $9.6 million in Q3 2023 year-over-year; TTM through Sep 2023 was $9.6 million, a N/A change, with the full-year FY2022 number at $2.1 million, changed N/A from a year prior.
  • Short term Debt was $9.6 million for Q3 2023 at Orchestra BioMed Holdings, up from $2.1 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $9.6 million in Q3 2023 to a low of $2.1 million in Q4 2022.